Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

U.S. Bioscience and Schering-Plough revise Ethyol agreement

Oct. 4, 1996

VX-853 for MDR reversal receives patent coverage

Oct. 4, 1996

Inhibitors of endothelial cell proliferation from Sumitomo

Oct. 4, 1996

Human Genome Sciences discloses novel approach to malignancy

Oct. 4, 1996

Anticancer MMP inhibitor enters clinical trials

Oct. 4, 1996

Takeda's anticancer drug pipeline reviewed

Sep. 27, 1996

Promising preclinical and clinical results for Genta's lead antisense compound

Sep. 27, 1996

Clinical benefits of p53 gene therapy

Sep. 27, 1996

Antisense compound displays activity in animal models of human cancer

Sep. 27, 1996

Clinical trial of gene therapy for malignant brain tumors

Sep. 27, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal
BioWorld
Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui...
Unique trial strategy muddies the ODAC waters for camizestrant
BioWorld
Following a discussion that focused more on a new personalized trial strategy rather than the proposed therapy, the U.S. FDA’s Oncologic Drugs Advisory Committee...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...